acid-phosphatase and Cardiovascular-Diseases

Disturbances in mineral metabolism and bone disease are common complications of chronic kidney disease (CKD). There is increasing evidence suggesting that these disorders in mineral and bone metabolism are associated with increased risk for cardiovascular calcification, morbidity, and mortality, especially among those who undergo maintenance dialysis. It is very important for dialysis patients to assess the mineral and bone abnormalities. Although bone biopsy is necessary to diagnosis of renal osteodystrophy in CKD-mineral and bone disorder (CKD-MBD) classification system, this technique is not recommended of routine evaluation for this bone disease. Bone metabolic markers, such as bone specific alkaline phosphatase and tartrate-resistant acid phosphatase isoform 5b, may be useful clinical indicator of bone turnover in CKD-MBD.

Topics: Acid Phosphatase; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Diseases, Metabolic; Cardiovascular Diseases; Chronic Disease; Dialysis; Humans; Isoenzymes; Kidney Diseases; Prognosis; Risk; Tartrate-Resistant Acid Phosphatase

Topics: Acid Phosphatase; Alkaline Phosphatase; Aspartate Aminotransferases; Biliary Tract Diseases; Cardiovascular Diseases; Clinical Enzyme Tests; Creatine Kinase; Esterases; Glucosephosphate Dehydrogenase; Humans; Isoenzymes; L-Lactate Dehydrogenase; Leucyl Aminopeptidase; Muscular Diseases; Neoplasms; Skin Diseases

Topics: Acid Phosphatase; Alkaline Phosphatase; Aspartate Aminotransferases; Biliary Tract Diseases; Cardiovascular Diseases; Clinical Enzyme Tests; Creatine Kinase; Esterases; Glucosephosphate Dehydrogenase; Humans; Isoenzymes; L-Lactate Dehydrogenase; Leucyl Aminopeptidase; Muscular Diseases; Neoplasms; Skin Diseases

Experiences resulting from Emcyt therapy in patients with both newly diagnosed and hormone refractory advanced prostate cancer, as well as on adjuvant to surgery or radiotherapy in earlier disease are presented. Data from trials of the National Prostatic Cancer Project (NPCP) and a series from Roswell Park Memorial Institute (RPMI) were divided into short-term (up to twenty weeks and up to fifty-two weeks in adjuvant trials) and long-term therapy. Baseline disease and patient characteristics and toxicities encountered in these two treatment-duration groups were compared. Patients in a more favorable health or disease status and/or responded to therapy were more frequently in the long-term group. Patients in the long-term group tended to have higher over-all incidences of toxicity; and although many had occurrences begin as early as those in the short-term group, they were able to tolerate the therapy for relatively long periods. The agent is thus both effective and can be given safety for long periods of time.

Topics: Acid Phosphatase; Alkaline Phosphatase; Anorexia; Cardiovascular Diseases; Clinical Trials as Topic; Diarrhea; Drug Administration Schedule; Estramustine; Humans; Male; Nausea; Neoplasm Staging; Nitrogen Mustard Compounds; Probability; Prostatic Neoplasms; Time Factors; Vomiting

Topics: Acid Phosphatase; Cardiovascular Diseases; Clinical Trials as Topic; Diethylstilbestrol; Follow-Up Studies; Humans; Male; Placebos; Prostatectomy; Prostatic Neoplasms; Testis; Time Factors

Topics: Acid Phosphatase; Aged; Carcinoma; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Diethylstilbestrol; Electrocardiography; Heart Failure; Humans; Ischemia; Male; Myocardial Infarction; Neoplasm Metastasis; Placebos; Plasminogen; Prognosis; Prostate; Prostatic Neoplasms; Pulmonary Embolism

The increased vascular calcification, cardiovascular morbidity, and mortality in chronic kidney disease (CKD) patients has been associated with disturbances in mineral-bone metabolism. In order to determine markers of the vascular calcification frequently observed in these patients, blood samples of elderly male and female hemodialysis CKD patients were used to measure serum levels of: osteoprotegerin (OPG), total soluble receptor activator of nuclear factor-κB ligand (sRANKL), and fetuin-A by enzyme immunoassay; tartrate-resistant acid phosphatase (TRACP-5b), and bone-specific alkaline phosphatase (BAP) by immunoenzymometric assay; osteocalcin (OC) by ELISA; iPTH by immunoradiometric assay; 25(OH)D(3) and 1,25(OH)(2)D(3), by I(125) radioimmunoassay; and calcium and phosphorus by photometric assay. Serum OPG, BAP, iPTH, phosphorus, and OC levels were higher and serum 25(OH)D(3), 1,25(OH)(2)D(3), and fetuin-A levels lower in both male and female CKD patients than in their respective controls. Our results indicate that the bone formation and resorption parameters are altered in elderly male and female hemodialysis CKD patients. These changes may lead to vascular calcifications and cardiovascular complications, given that elevated OPG and OC levels and reduced fetuin-A levels are associated with cardiovascular events.

Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; alpha-2-HS-Glycoprotein; Biomarkers; Cardiovascular Diseases; Female; Humans; Isoenzymes; Male; Middle Aged; Osteoprotegerin; RANK Ligand; Renal Dialysis; Renal Insufficiency, Chronic; Tartrate-Resistant Acid Phosphatase; Vascular Calcification

The effects of co-administration of artesunate and amodiaquine on some cardiovascular disease indices were investigated in albino rats (Rattus novergicus). The experimental animals were randomly divided into four groups: those administered distilled water (control), those administered artesunate (2 mg/kg body weight), those administered amodiaquine (6.12 mg/kg body weight) and those co-administered artesunate (2 mg/kg body weight) and amodiaquine (6.12 mg/kg body weight). The drugs were orally administered twice daily for three days after which the serum lipid profile, heart MDA content and heart ALP and ACP activities were determined. Artesunate significantly reduced (P<0.05) total cholesterol and HDL-cholesterol concentrations in the serum with no significant effects (P>0.05) on other parameters compared to controls. Amodiaquine, on the other hand, significantly reduced (P<0.05) serum total cholesterol concentration while it significantly increased (P<0.05) serum LDL-cholesterol and heart ACP activity compared to controls. Co-administration of artesunate and amodiaquine significantly reduced (P<0.05) total cholesterol and HDL-cholesterol concentrations in the serum while significantly increasing (P<0.05) serum LDL-cholesterol concentration, atherogenic index (LDL-C/HDL-C) and ACP activity in the heart compared to controls. The results obtained suggest that co-administration of artesunate and amodiaquine to patients with coronary heart disease should be with caution.

Topics: Acid Phosphatase; Alkaline Phosphatase; Amodiaquine; Animals; Artemisinins; Artesunate; Cardiovascular Diseases; Cholesterol; Malondialdehyde; Myocardium; Rats

This study was undertaken to determine the association between serum tartrate-resistant acid phosphatase 5a (TRACP5a) and cardiovascular disease (CVD) risk.. Four hundred patients were enrolled including, 291 asymptomatic subjects grouped by the number of traditional risk factors, 36 patients undergoing cardiac arteriography, 34 undergoing percutaneous cardiac intervention, and 39 with acute myocardial infarction. Serum was collected at baseline and, in arteriograpy and intervention groups, periodically for 1 week afterward. In addition to laboratory and clinical evaluation for risk assessment, serum TRACP5a, C-reactive protein (CRP) and interleukin-6 (IL-6) were determined.. All biomarkers rose with increasing CVD risk. Only serum TRACP5a, logCRP and cholesterol were elevated in symptomatic patients. Serum TRACP5a was higher in men and correlated with age, logCRP, logIL-6 and log-triglycerides, and in symptomatic patients, with the number of diseased coronary arteries. IL-6 and CRP showed acute phase responses, whereas TRACP5a did not change over 1 week after arteriography or intervention. After adjustment for all other variables and risk factors, TRACP5a and logCRP were the only biomarkers to associate with symptomatic disease. TRACP5a was more specific than CRP to predict myocardial infarction among all subjects.. Serum TRACP5a is a macrophage-derived inflammation marker associated with CVD risk, and with coronary vessel disease and its severity and may be a useful marker for screening and assessment of CVD risk.

Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Female; Humans; Inflammation; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Risk Factors; Tartrate-Resistant Acid Phosphatase; Young Adult

Erythrocyte acid phosphatase (ACP locus 1), also known as low-molecular-weight protein tyrosine phosphatase, has previously been associated to glycemia, dyslipidemia, and obesity. In this study, ACP1 genotype and activity were tested in 318 women aged 19 to 83 (mean, 51.74 +/- 13.44) years. ACP1 genotype was found to directly correlate to glutathione reductase activity (P < .001) and levels of low-density lipoprotein cholesterol (P = .038). Glutathione reductase activity was in turn found to correlate to a series of cardiovascular risk factors such as systolic arterial pressure (P < .001), total cholesterol levels (P = .018), and low-density lipoprotein cholesterol levels (P = .039). A possible protective effect of ACP1 genotype AA against these cardiovascular risk factors was observed in this study. Furthermore, this work hypothesizes that nutritional riboflavin uptake becomes more crucial as body mass index increases, to counteract oxidative stress and minimize cardiovascular risk. This might be especially true in ACP1 genotypes AC, BC, and CC, which might possibly show the least endogenous protection against oxidative stress.

Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Erythrocytes; Female; Genotype; Glutathione Reductase; Homeostasis; Humans; Middle Aged; Nutritional Physiological Phenomena; Obesity; Oxidative Stress; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins; Riboflavin; Risk Assessment; Young Adult

Recent studies have indicated a link between bone metabolism and cardiovascular events in patients with chronic kidney disease (CKD). CKD is a major health problem worldwide. This study evaluates the role of noninvasive markers of bone metabolism in predicting cardiovascular morbidity (coronary artery disease, peripheral vascular disease, stroke) and mortality in patients with mild to severe forms of CKD. In a prospective cohort study, 627 patients with CKD were screened. To focus on bone metabolism, traditional risk factors for cardiovascular events were excluded, and 135 patients with CKD stages 1-5 were followed for 4 yr. Glomerular filtration rate was calculated by the Modification of Diet in Renal Disease formula. PTH (measured by four different assays), vitamin D 25 and 1,25, bone-specific alkaline phosphatase (BSALP), TRACP-5b, osteocalcin, serum collagen cross-link molecules, RANKL, and osteoprotegerin were determined. Predictors of cardiovascular events were evaluated by multivariable logistic regression, Kaplan-Meier survival, and Cox regression analysis. There were a total of 45 cardiovascular events (33%). Event rates were 5.6%, 29.1%, 45.2%, and 45.0% in CKD stages 1-2, 3, 4, and 5, respectively. In logistic regression, cardiovascular events were predicted only by (1) CKD stage (independent of age or sex; p < 0.001); (2) BSALP (p = 0.03); and (3) TRACP-5b (p = 0.04). Markers of bone formation (BSALP) and resorption (TRACP-5b) can serve as predictors of cardiovascular morbidity and mortality in CKD.

Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone and Bones; Cardiovascular Diseases; Demography; Female; Humans; Isoenzymes; Kidney Failure, Chronic; Male; Middle Aged; Organ Specificity; Prognosis; Proportional Hazards Models; Regression Analysis; Survival Analysis; Tartrate-Resistant Acid Phosphatase

To correlate, in a sample of healthy children and adolescents, the activity of the enzyme acid phosphatase (ACP) with its different genetic phenotypes and of these with some cardiovascular risk parameters such as body mass index (BMI), percentage of total fat mass (%TFM), trunk fat (TF), insulin resistance, and the arterial blood pressure (BP).. The sample was composed of 173 healthy children and adolescents, 96 (55.5%) F and 77 (44.5%) M, with ages between 10 and 16 years (mean: 13.04 +/- 1.68). The ACP activity was determined through a spectrophotometric method and its phenotypes through isoelectric focusing electrophoresis. BMI (Kg/m2) and the BP were obtained by standardized methods. Glycemia determined by the glucose oxidase method and insulinemia by RIA method. Insulin resistance based on the homeostasis model assessment (HOMA) was calculated as: [fasting insulin (microU/ml) x fasting glucose (mmol/l)]: 22.5. The %TFM and TF were determined by dual energy x-ray absorptiometry (DXA). The statistical methods used were ANOVA, the Pearson correlation and the Student's test.. The distribution of the phenotypes were the following--absolute versus relative frequencies: BB-74 (48.4%), AB-52 (34%), AA-16 (10.5%), BC-7 (4.6%), AC-3 (2%) and CC-1 (0.7%). ACP activities (mean: 321.04 +/- 84.56) were significantly different among the phenotypes (p < 0.001). The smallest activity was observed in the AA individuals, the highest in CC, followed by BC (247.17 +/- 66.52 and 767.30 and 362.44 +/- 91.56 respectively). Glycemia was higher in the AA individuals (4.61 +/- 0.37) compared to CC + BC (4.40 +/- 0.31) (p = 0.08). A direct correlation was verified between HOMA and BP, both diastolic (p = 0.013, r = 0.250) and systolic (p = 0.015, r = 0.246), as well as of these with BMI (mean: 20.57 +/- 3.24) and insulinemia (p = 0.016, r = 0.215; p = 0.004, r = 0.280 and p = 0.007, r = 0.240; p = 0.008, r = 0.261 respectively for diastolic and systolic BP). There were no significant difference of BMI between sexes, nor of this as well as of % TFM and TF among the different genetic phenotypes of ACP.. The smallest enzymatic activity of ACP seems to be associated with the AA individuals, where a trend for higher glycemia was verified. BMI, HOMA and insulinemia, due to their significant direct relationship with diastolic and systolic BP in this sample of children and adolescents may warrant more future attention in the evaluation of cardiovascular risk. There were no significant differences of HOMA, BMI, %TFM, TF nor of BP among the different ACP genetic phenotypes.

Topics: Acid Phosphatase; Adolescent; Cardiovascular Diseases; Child; Erythrocytes; Female; Humans; Male; Polymorphism, Genetic; Risk Factors

Although the clinical expression of cardiovascular disease usually occurs in adulthood, it is unanimously accepted that atherosclerosis begins in the pediatric age. Because of the early onset of the disease, it is of great importance to screen for major risk factors since pre-school age, especially in risk families. Recent investigations have shown a great interest not only in studying the classic risk factors, but also in the evaluation of oxidative stress and the main antioxidant defense systems. The major cause of this interest is the knowledge of the deleterious effect of reactive oxygen species on lipids, the endothelial membrane of arteries and, finally, on the occurrence of cardiovascular disease.. 51 children of both genders, aged 9-12 years, randomly selected from a rural community, were observed. A possible association between low molecular acid phosphatase genetic polymorphism of the erythrocyte and the prooxidant status markers (epinephrine oxidase and low molecular protein phosphotyrosine phosphatase from the erythrocyte), some enzymatic systems of the body antioxidant defense (transmembranar reductase of ferricyanide and metahemoglobin reductase) and finally some intermediate phenotypes of cardiovascular disease (lipid profile and blood pressure) were studied.. The study of prooxidant status markers and antioxidant enzymes shows significant differences for acid phosphatase and epinephrine oxidase activities in relation to low molecular acid phosphatase genetic polymorphism, the highest values observed being in those homozygous to the B allele (p < 0.05). The inter-relation study between variables showed, among other things, a significant inverse correlation between acid phosphatase and transmembrane reductase and a direct correlation between apolipoprotein B, acid phosphatase and metahemoglobin reductase. A positive family history for cardiovascular disease also showed a direct and significant correlation to total cholesterol, LDL-cholesterol and apolipoprotein B.. The polymorphic variants of low molecular acid phosphatase and protein phosphotyrosine phosphatase with greater activity are strongly associated, not with the classic parameters of cardiovascular risk factors, but with oxidative stress indicators, such as low molecular protein phosphotyrosine phosphatase and epinephrine oxidase. Family history indicators of cardiovascular risk are clearly associated, since early ages, to some conventional risk factors, such as lipid profile and blood pressure.

Topics: Acid Phosphatase; Cardiovascular Diseases; Child; Female; Humans; Male; Multivariate Analysis; Polymorphism, Genetic; Risk Factors

A large pedigree with high prevalence of heart disease is investigated to analyse the association between polymorphic blood markers and quantitative risk factors for cardiovascular disease. The analysis incorporates a familial correlation structure among the individuals in the pedigree and a generalized power transformation to induce approximate residual normality of the risk factors. A total of 380 marker/risk factor combinations are analysed, and at the normal 1% significance level, positive associations are found between the A antigen of the ABO locus and both serum total cholesterol and low-density lipoprotein cholesterol, and negative associations are found between the B antigen of the ABO locus and serum total cholesterol, and between the B allele of acid phosphatase (AP) locus and systolic blood pressure.

Topics: ABO Blood-Group System; Acid Phosphatase; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Genetic Markers; Humans; Male; Polymorphism, Genetic; Risk Factors

Topics: Acid Phosphatase; Adenocarcinoma; Aged; Cardiovascular Diseases; Castration; Diethylstilbestrol; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Placebos; Prognosis; Prostatectomy; Prostatic Neoplasms; Rectum

Topics: Acid Phosphatase; Aged; Cardiovascular Diseases; Humans; Hypertension; Male; Middle Aged; Prolactin; Prostate; Prostatic Neoplasms; Protein Binding; Reserpine; Testosterone

Topics: Acid Phosphatase; Bone Marrow Diseases; Cardiovascular Diseases; Clinical Enzyme Tests; Heart Diseases; Histocytochemistry; Humans; Leukocytes; Neoplasm Metastasis; Neoplasms; Thyroid Diseases

Topics: Acid Phosphatase; Aspartate Aminotransferases; Cardiovascular Diseases; Clinical Enzyme Tests; Fructose-Bisphosphate Aldolase; Humans; Isoenzymes; L-Lactate Dehydrogenase; Malate Dehydrogenase; Myocardial Infarction; Succinate Dehydrogenase